Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 321 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Early-onset cancer: why are more young adults being diagnosed? January 24, 2023 EMA Recommends Granting a Marketing Authorisation for Capmatinib May 13, 2022 How I Learned to Advocate for Myself During Cancer: “Your Stories”... October 18, 2022 FDA Approves Osimertinib as Adjuvant Therapy for NSCLC with EGFR Exon... January 5, 2021 Load more HOT NEWS Research with Integrity – the madness of short methods Preclinical Study May Have Found New Treatment Option for Triple-Negative Breast... Tarlatamab Demonstrates Sustained Clinical Benefit and Potential Findings of Intracranial Activity... How Wartime Violence Against Women Is Hurting Millions Worldwide
